These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 321176)

  • 1. Effect of triamterene on potassium excretion in cirrhotic patients receiving furosemide.
    Thompson EJ; Torres E; Grosberg SJ; Martinez-Maldonado M
    Clin Pharmacol Ther; 1977 Apr; 21(4):392-4. PubMed ID: 321176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics and dynamics of triamterene at steady-state in patients with cirrhosis.
    Dao MT; Villeneuve JP
    Clin Invest Med; 1988 Feb; 11(1):6-9. PubMed ID: 3365882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative study of diuretic drugs used in cirrhotic and ascitic patients].
    Lennhoff M; Duhalt R; Peña JC
    Rev Invest Clin; 1968; 20(2):165-80. PubMed ID: 5721631
    [No Abstract]   [Full Text] [Related]  

  • 4. [Controlled clinical trial of the association of furosemide and triamterene].
    Azzi E; Perraro F
    Clin Ter; 1971 Mar; 56(6):501-22. PubMed ID: 5131091
    [No Abstract]   [Full Text] [Related]  

  • 5. High doses of spironolactone (Aldactone, SC-14266, Verospirone) alone and in combination with triamterene and-or diuretics in the treatment of refractory edema associated with secondary hyperaldosteronism.
    Radó JP; Marosi J; Takó J
    Endokrinologie; 1970; 57(1):46-62. PubMed ID: 4923990
    [No Abstract]   [Full Text] [Related]  

  • 6. Reversal of the suppressed potassium excretion during treatment with combinations of antikaliuretic drugs (spironolactone, canrenone, triamterene, amiloride) in patients with liver cirrhosis.
    Radó JP; Sawinsky I; Juhos E
    Int J Clin Pharmacol Biopharm; 1976 Oct; 14(3):163-7. PubMed ID: 1002353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuation of the kaluretic properties of furosemide by triamterene (Dyrenium) in healthy volunteers.
    Levinson B; Shenouda M; Stypinski D
    Int J Clin Pharmacol Ther; 2005 Feb; 43(2):92-100. PubMed ID: 15726878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Triamterene in the depletive treatment of cirrhosis].
    Ravenni G; Rubegni M; Forconi S
    Boll Soc Ital Biol Sper; 1964 Apr; 40(7):290-3. PubMed ID: 5875781
    [No Abstract]   [Full Text] [Related]  

  • 9. [Association of furosemide and amiloride in patients with essential hypertension. Effect on the excretion of Na, K, Cl and on urine volume].
    Chávez de Los Rios JM; Otero Cagide F; Alfaro Cano L; Gatica Laborde V
    Prensa Med Mex; 1978; 43(3-4):89-94. PubMed ID: 364462
    [No Abstract]   [Full Text] [Related]  

  • 10. [An experimental and clinical pharmacological study of the influence of triamterene on the diuretic and saluretic properties of furosemide xantinol].
    Celdrán E; Bekett PR; Roberts DJ
    Arzneimittelforschung; 1976; 26(11):2073-6. PubMed ID: 14648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [ON MODIFICATIONS OF PLASMA AND URINARY ELECTROLYTES IN ASCITOGENIC HEPATIC CIRRHOSIS IN TREATMENT WITH TRIAMTERENE ALONE AND ASSOCIATED WITH HYDROCHLOROTHIAZIDE AND WITH SPIRONOLACTONE].
    MELLONI GF; BARATTA C; MARANGONI R; MERLO L; ANTOGNETTI R
    Minerva Med; 1964 Sep; 55():2722-37. PubMed ID: 14199461
    [No Abstract]   [Full Text] [Related]  

  • 12. Stepped care medical treatment for cirrhotic ascites: analysis of factors influencing the response to treatment.
    Takaya A; Fukui H; Matsumura M; Uemura M; Kojima H; Okamoto S; Tsujii T
    J Gastroenterol Hepatol; 1995; 10(1):30-5. PubMed ID: 7620104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic study of the combination of furosemide retard and triamterene.
    Loew D; Barkow D; Schuster O; Knoell HE
    Eur J Clin Pharmacol; 1984; 26(2):191-5. PubMed ID: 6723757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pathogenesis and therapy of ascites in liver cirrhosis].
    Dölle W
    Internist (Berl); 1966 Jan; 7(1):48-54. PubMed ID: 4861685
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical evaluation of the use of diuretics in the ascitic phase of hepatic cirrhosis].
    Castagnolo B; De Colibus V; Napolitano L; Aliperta A; Caldarelli G; Abignente F
    Clin Ter; 1977 Dec; 83(6):625-9. PubMed ID: 343976
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative analysis of torasemide and furosemide in liver cirrhosis.
    Fiaccadori F; Pasetti GC; Pedretti G; Pizzaferri P; Elia GF
    Cardiology; 1994; 84 Suppl 2():80-6. PubMed ID: 7954549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacy of furosemide with two furosemide-triamterene combinations in the treatment of cardiac insufficiency.
    Saarimaa H; Ojasalo T
    J Int Med Res; 1985; 13(4):236-40. PubMed ID: 4043516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative pharmacodynamics of furosemide and muzolimine in cirrhosis. Study on renal sodium and potassium handling and renin-aldosterone axis.
    Bernardi M; De Palma R; Trevisani F; Santini C; Servadei D; Gasbarrini G
    Z Kardiol; 1985; 74 Suppl 2():129-34. PubMed ID: 3890391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of cirrhotic edemas with triamterene, amiloride and spirolactone. New clinical and biological facts].
    Vesin P
    Schweiz Med Wochenschr; 1971 Mar; 101(11):398-401. PubMed ID: 5558553
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical experience with furosemide.
    Herrmann GR; Ghiselli RG
    South Med J; 1968 Oct; 61(10):1083-8. PubMed ID: 5746300
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.